lupus |
Disease ID | 1489 |
---|---|
Disease | lupus |
Manually Symptom | (Waiting for update.) |
Text Mined Symptom | UMLS | Name | Sentences' Count(Total Symptoms:2) |
Manually Genotype(Total Text Mining Genotypes:0) |
---|
(Waiting for update.) |
All Snps(Total Genotypes:17) | |||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
snpId | pubmedId | geneId | geneSymbol | diseaseId | sourceId | sentence | score | Year | geneSymbol_dbSNP | CHROMOSOME | POS | REF | ALT |
rs10516487 | 21900951 | 55024 | BANK1 | umls:C0024131 | BeFree | The dual effect of the lupus-associated polymorphism rs10516487 on BANK1 gene expression and protein localization. | 0.000542884 | 2012 | BANK1 | 4 | 101829919 | G | T,A |
rs1143679 | 24608226 | 3684 | ITGAM | umls:C0024131 | BeFree | Combined protein- and nucleic acid-level effects of rs1143679 (R77H), a lupus-predisposing variant within ITGAM. | 0.002171535 | 2015 | ITGAM | 16 | 31265490 | G | A |
rs1143679 | 22586164 | 3684 | ITGAM | umls:C0024131 | BeFree | The rs1143679 (R77H) lupus associated variant of ITGAM (CD11b) impairs complement receptor 3 mediated functions in human monocytes. | 0.002171535 | 2012 | ITGAM | 16 | 31265490 | G | A |
rs1270942 | 21952918 | 3663 | IRF5 | umls:C0024131 | BeFree | Importantly, our data suggest that in patients with lupus, the presence of the HLA lupus risk alleles in rs1270942 and rs3131379 increases the odds of also carrying the lupus risk allele in IRF5 (rs2070197) by 17% and 16%, respectively (P = 0.0028 and P = 0.0047, respectively). | 0.003800186 | 2012 | CFB | 6 | 31951083 | A | G |
rs13023380 | 23441136 | 2547 | XRCC6 | umls:C0024131 | BeFree | DNA carrying the intronic risk allele rs13023380 showed reduced binding efficiency to a cellular protein complex including nucleolin and lupus autoantigen Ku70/80, and showed reduced transcriptional activity in vivo. | 0.000542884 | 2013 | IFIH1 | 2 | 162297853 | G | A |
rs13023380 | 23441136 | 4691 | NCL | umls:C0024131 | BeFree | DNA carrying the intronic risk allele rs13023380 showed reduced binding efficiency to a cellular protein complex including nucleolin and lupus autoantigen Ku70/80, and showed reduced transcriptional activity in vivo. | 0.000271442 | 2013 | IFIH1 | 2 | 162297853 | G | A |
rs1391511 | 20662065 | 1316 | KLF6 | umls:C0024131 | GAD | [These results suggest that variation near genes related to inflammatory and apoptotic responses may promote cardiac injury initiated by passively acquired autoantibodies.] | 0.002367032 | 2010 | LINC00704;LOC105376373 | 10 | 4677604 | A | G |
rs2070197 | 21952918 | 3663 | IRF5 | umls:C0024131 | BeFree | Importantly, our data suggest that in patients with lupus, the presence of the HLA lupus risk alleles in rs1270942 and rs3131379 increases the odds of also carrying the lupus risk allele in IRF5 (rs2070197) by 17% and 16%, respectively (P = 0.0028 and P = 0.0047, respectively). | 0.003800186 | 2012 | IRF5 | 7 | 128948946 | T | C |
rs2476601 | 18759295 | 26191 | PTPN22 | umls:C0024131 | BeFree | The PTPN22 C1858T polymorphism is associated with skewing of cytokine profiles toward high interferon-alpha activity and low tumor necrosis factor alpha levels in patients with lupus. | 0.003181358 | 2008 | PTPN22;AP4B1-AS1 | 1 | 113834946 | A | G |
rs2476601 | 23359562 | 26191 | PTPN22 | umls:C0024131 | BeFree | The protein tyrosine phosphatase LYP, a key regulator of TCR signaling, presents a single nucleotide polymorphism, C1858T, associated with several autoimmune diseases such as type I diabetes, rheumatoid arthritis, and lupus. | 0.003181358 | 2013 | PTPN22;AP4B1-AS1 | 1 | 113834946 | A | G |
rs2476601 | 18759295 | 7124 | TNF | umls:C0024131 | BeFree | The PTPN22 C1858T polymorphism is associated with skewing of cytokine profiles toward high interferon-alpha activity and low tumor necrosis factor alpha levels in patients with lupus. | 0.008262808 | 2008 | PTPN22;AP4B1-AS1 | 1 | 113834946 | A | G |
rs2476601 | 23359562 | 52 | ACP1 | umls:C0024131 | BeFree | The protein tyrosine phosphatase LYP, a key regulator of TCR signaling, presents a single nucleotide polymorphism, C1858T, associated with several autoimmune diseases such as type I diabetes, rheumatoid arthritis, and lupus. | 0.000271442 | 2013 | PTPN22;AP4B1-AS1 | 1 | 113834946 | A | G |
rs3099844 | 20662065 | 352961 | HCG26 | umls:C0024131 | GAD | [These results suggest that variation near genes related to inflammatory and apoptotic responses may promote cardiac injury initiated by passively acquired autoantibodies.] | 0.002367032 | 2010 | LOC102725068 | 6 | 31481199 | C | A |
rs3131379 | 21952918 | 3663 | IRF5 | umls:C0024131 | BeFree | Importantly, our data suggest that in patients with lupus, the presence of the HLA lupus risk alleles in rs1270942 and rs3131379 increases the odds of also carrying the lupus risk allele in IRF5 (rs2070197) by 17% and 16%, respectively (P = 0.0028 and P = 0.0047, respectively). | 0.003800186 | 2012 | MSH5;MSH5-SAPCD1 | 6 | 31753256 | G | A |
rs3813946 | 17360460 | 1380 | CR2 | umls:C0024131 | BeFree | Single-nucleotide polymorphism 1 (rs3813946), located in the 5' untranslated region of the CR2 gene, altered transcriptional activity, suggesting a potential mechanism by which CR2 could contribute to the development of lupus. | 0.000814326 | 2007 | CR2 | 1 | 207454348 | T | C |
rs72556554 | 21937424 | 11277 | TREX1 | umls:C0024131 | BeFree | The TREX1 exonuclease R114H mutation in Aicardi-Goutières syndrome and lupus reveals dimeric structure requirements for DNA degradation activity. | 0.001628651 | 2011 | TREX1 | 3 | 48466996 | G | A,C |
rs743446 | 20662065 | 2078 | ERG | umls:C0024131 | GAD | [These results suggest that variation near genes related to inflammatory and apoptotic responses may promote cardiac injury initiated by passively acquired autoantibodies.] | 0.002367032 | 2010 | NA | 21 | 38684499 | A | C |
GWASdb Annotation(Total Genotypes:0) | |
---|---|
(Waiting for update.) |
GWASdb Snp Trait(Total Genotypes:0) | |
---|---|
(Waiting for update.) |
Mapped by lexical matching(Total Items:0) |
---|
(Waiting for update.) |
Mapped by homologous gene(Total Items:0) |
---|
(Waiting for update.) |
Chemical(Total Drugs:0) | |
---|---|
(Waiting for update.) |
FDA approved drug and dosage information(Total Drugs:0) | |
---|---|
(Waiting for update.) |
FDA labeling changes(Total Drugs:0) | |
---|---|
(Waiting for update.) |